Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Natural/Health Food Industry Stocks -- Ignore unavailable to you. Want to Upgrade?

To: J. M. Burr who wrote (109)	11/17/1998 8:50:00 PM
From: organicgerry	Respond to of 337

I posted this a while back: Message 6330240 GNCI may be a good short term play because it has been beaten down so bad. But I am more of a long term investor so I would personally stay away from this one. TWLB is another story. They are growing fast and seem to emerging as an industry leader in a fragmented industry where consolidation will be inevitable. In spite of this, they are priced at a low p/e of around 18. I recently added to my position. As I mentioned before, I don't think the earnings story will be the same for TWLB as for the generics. Once the nervous market sees that TWLB's earnings will continue to grow ZACKs shows TWLB earnings growing from 1.34 to 1.67 next year, or 25%. 25 times 1.67 gives a price of $41.75. I wouldn't be surprised if they exceed these expectations, but even at this valuation its a double in one year. See: www1.zacks.com